Alector Inc (NASDAQ:ALEC)

7.42
Delayed Data
As of Jun 06
 +0.23 / +3.20%
Today’s Change
5.76
Today|||52-Week Range
13.50
-19.61%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$593.5M

Company Description

Alector, Inc. operates as a clinical-stage biopharmaceutical company, which engages in pioneering of immuno-neurology. It develops portfolio of innate immune system programs, designed to functionally repair genetic mutations and enable the rejuvenated immune cells to counteract emerging brain pathologies. Its treatment targets immune dysfunction as a root cause of multiple pathologies that are drivers of degenerative brain disorders. The company was founded by Asa Abeliovich, Errik B. Anderson, Tillman U. Gerngross, and Arnon Rosenthal in May 2013 and is headquartered in South San Francisco, CA.

Contact Information

Alector, Inc.
131 Oyster Point Boulevard
South San Francisco California 94080-2029
P:(415) 231-5660
Investor Relations:
(202) 549-0557

Employees

Shareholders

Individual stakeholders36.65%
Mutual fund holders36.51%
Other institutional33.44%

Top Executives

Arnon RosenthalChief Executive Officer & Director
Saraswati Kenkare-MitraPresident, Head-Research & Development
Marc Edward GrassoChief Financial, Accounting & Business Officer
Charles WolfusVP-Technology & Digital Health
Gary RomanoChief Medical Officer